Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Buy
55
ARQT Quote, Financials, Valuation and Earnings
Last price:
$14.22
Seasonality move
:
42.46%
Day range:
$14.20 - $15.03
52-week range:
$3.07 - $15.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.74x
P/B ratio:
10.69x
Volume:
1.6M
Avg. volume:
2.1M
1-year change:
373.51%
Market cap:
$1.7B
Revenue:
$59.6M
EPS (TTM):
-$1.79
Analysts' Opinion
-
Consensus RatingArcutis Biotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.00, Arcutis Biotherapeutics has an estimated upside of 32.87% from its current price of $14.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 16.08% downside risk from its current price of $14.30.
Fair Value
-
According to the consensus of 5 analysts, Arcutis Biotherapeutics has 32.87% upside to fair value with a price target of $19.00 per share.
ARQT vs. S&P 500
-
Over the past 5 trading days, Arcutis Biotherapeutics has overperformed the S&P 500 by 0.67% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arcutis Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcutis Biotherapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Arcutis Biotherapeutics reported revenues of $44.8M.
Earnings Growth
-
Arcutis Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arcutis Biotherapeutics reported earnings per share of -$0.33.
Enterprise value:
1.5B
EV / Invested capital:
4.28x
Price / LTM sales:
11.74x
EV / EBIT:
--
EV / Revenue:
11.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$124.2M
Return On Assets:
-49.01%
Net Income Margin (TTM):
-140.97%
Return On Equity:
-138.99%
Return On Invested Capital:
-56.93%
Operating Margin:
-87.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $49M | $138.7M | $38.1M | $44.8M | |
| Gross Profit | $456K | $45.8M | $124.2M | $36.9M | $39.3M | |
| Operating Income | -$304.5M | -$248.4M | -$181.9M | -$36.9M | -$39.1M | |
| EBITDA | -$301.3M | -$234.5M | -$163.3M | -$33.8M | -$33.5M | |
| Diluted EPS | -$5.89 | -$4.38 | -$1.79 | -$0.73 | -$0.33 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $194.1M | $381.8M | $496.7M | $281.5M | $423.7M | |
| Total Assets | $198M | $387M | $508.9M | $293M | $437.4M | |
| Current Liabilities | $21.2M | $19.1M | $37.1M | $41.9M | $172.4M | |
| Total Liabilities | $24.9M | $24M | $238.1M | $246.2M | $280.7M | |
| Total Equity | $173.1M | $363M | $270.8M | $46.7M | $156.6M | |
| Total Debt | -- | -- | $196.8M | $200.8M | $204.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$238.4M | -$261.9M | -$167.7M | -$44M | -$34.7M | |
| Cash From Investing | -$105.9M | $284.6M | -$68.2M | $45.5M | $84.8M | |
| Cash From Financing | $373.7M | $3M | $262.9M | $867K | $394K | |
| Free Cash Flow | -$261.8M | -$262.4M | -$167.8M | -$44M | -$34.8M | |
ARQT
Sector
Market Cap
$1.7B
$45.9M
Price % of 52-Week High
90.56%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-24.04%
-0.6%
1-Year Price Total Return
373.51%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$14.57
200-day SMA
Buy
Level
$9.93
Bollinger Bands (100)
Buy
Level
8.74 - 12.2
Chaikin Money Flow
Sell
Level
-26.1M
20-day SMA
Buy
Level
$13.43
Relative Strength Index (RSI14)
Buy
Level
60.67
ADX Line
Buy
Level
20
Williams %R
Neutral
Level
-40.0538
50-day SMA
Buy
Level
$11.12
MACD (12, 26)
Buy
Level
1.05
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
92.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.3294)
Sell
CA Score
(Annual)
Level (-3.5853)
Sell
Beneish M-Score
(Annual)
Level (10.1235)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.9157)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Stock Forecast FAQ
In the current month, ARQT has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARQT average analyst price target in the past 3 months is $19.00.
-
Where Will Arcutis Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcutis Biotherapeutics share price will rise to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Arcutis Biotherapeutics?
Analysts are divided on their view about Arcutis Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcutis Biotherapeutics is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Arcutis Biotherapeutics's Price Target?
The price target for Arcutis Biotherapeutics over the next 1-year time period is forecast to be $19.00 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ARQT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcutis Biotherapeutics is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARQT?
You can purchase shares of Arcutis Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcutis Biotherapeutics shares.
-
What Is The Arcutis Biotherapeutics Share Price Today?
Arcutis Biotherapeutics was last trading at $14.22 per share. This represents the most recent stock quote for Arcutis Biotherapeutics. Yesterday, Arcutis Biotherapeutics closed at $14.30 per share.
-
How To Buy Arcutis Biotherapeutics Stock Online?
In order to purchase Arcutis Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 1.93% over the past day.
Sell
50
TSLL alert for Dec 30
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 4.72% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 9.72% over the past day.
